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INTRODUCTION 
Epidemiology and classification of diabetes mellitus 
Diabetes mellitus (DM) is a heterogeneous disease characterised by hyperglycaemia and is among 
the diseases responsible for most of the morbidities and mortalities worldwide. Definitive diabetes 
affects nearly 8.5% of the total population [1], and 23.8 % of the disease might remain 
undiscovered [2]. The prevalence of DM doubled in the last three decades, meaning that 422 
million people were affected in 2014, and 3.7 million people died because of diabetes or supra-
normal blood sugar level [1].  
In accordance with the WHO guideline of classification on DM [3] there are four main types of 
diabetes: type 1 diabetes (T1DM), type 2 diabetes (T2DM), other specific diabetes (i.e. monogenic 
diabetes) and diabetes associated with pregnancy. Ninety per cent of the patients have T2DM, 
where the most predisposing factors are obesity and an unhealthy lifestyle, which is leading to and 
enhancing the insulin resistance (IR). [4]. Most of the people affected by T2DM are overweight or 
obese based on the body mass index calculations. However, considerable number of patients 
diagnosed with T2DM are not reaching the threshold level of obesity by the BMI criteria, while 
they have a higher portion of body fat, mainly in the abdominal region [5]. In T1DM, both 
genetical and environmental factors can cause pancreatic β-cell loss and consequential absolute 
lack of insulin. T1DM develops mostly during childhood, but it can develop in adults as well. The 
previous autoimmune or non‑autoimmune categories were rejected in the recent nomenclature [3]. 
Pathophysiology of diabetes mellitus 
In diabetes, the pancreas β-cell dysfunction spread on a broad spectrum and progressing with time. 
Under physiological conditions, the insulin secretion is in balance with the insulin need due to the 
adaptation capability of the pancreatic β-cells. The relationship between β-cell function and the 
insulin sensitivity can be depicted as a hyperbola [6]. Deviation from the normal curve happens 
when the disease is in the phase of impaired glucose tolerance or the definitive T2DM stage. β-
cells tend to produce more insulin to maintain the normal blood glucose level; this circulous 
vitiousus is leading to β-cell exhaustion. Despite the compensatory capacity of the β-cells, it has 
been shown that β-cells cannot renew themselves after 30 years of age [7]. 
Insulin resistance is a stage on the diabetes spectra when the tissues have a decreased response to 
a normal circulating level of insulin. Insulin resistance is frequently associated with various 
disorders, such as obesity, dyslipidaemia, and hypertension. There are pathologic changes in 
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insulin receptor isoforms, the insulin signalling pathway is damaged, and the amount of 
inflammatory molecules are increased in the stage of the insulin resistance. Under physiological 
conditions, the insulin increases the glucose uptake by the tissues — mostly by skeletal muscles 
— reduces its production in the liver, and the fat tissue is less likely to release fatty acids. 
Conversely, insulin resistance results in higher fatty acid levels and hyperglycaemia which lead to 
impaired feedback and further insulin resistance deterioration [6]. The progressive 
pathophysiological changes in glucose utilisation can lead to the development of T2DM 
characterised with a heterogeneous pattern of the glucose level in the body.  Intracellular 
hypoglycaemia dominates 80% of the cells having insulin-dependent glucose transporters. In 
contrast there is a marked hyperglycaemia in the blood, and in the resting part of the cells having 
glucose transporters without a need of insulin, for instance, the endothelial cells, red blood cells, 
thrombocytes, pancreatic β-cells, renal glomerular cells.  
Molecular mechanisms involved in the complications 
The persistent intracellular hyperglycaemia activates cellular signalling pathway directly and 
through mitochondrial superoxide overproduction [8], causing intra- and extracellular damage. 
One of these mechanisms is the polyol pathway flux. Under physiological conditions, the aldose 
reductase enzyme turns the toxic aldehydes into inactive alcohols in the cell. The enzyme has a 
low affinity to glucose at normal glucose level. However, in intracellular hyperglycaemia, this 
enzyme acts as a catalysator for the reduced nicotinamide adenine dinucleotide phosphate 
(NADPH)-dependent reduction of glucose to sorbitol and at the end to fructose [9]. The lack in 
the given NADPH is resulting in a decreased production of reduced glutathione (GSH) from 
glutathione disulphide (GSSG). Since the NADPH is a crucial cofactor for the glutathione 
reductase enzyme, this phenomenon enhances the oxidative stress in the cell.  Sorbitol molecules 
penetrate poorly through the cell membrane, thus the increased sorbitol level causing osmotic 
stress in the cell. Moreover, the metabolites of fructose enhance advanced glycation end products 
(AGEs) formation. 
The formation of the AGEs leads to intracellular (IC) and extracellular (EC) protein damage and 
dysfunction. Abnormal interaction between the extracellular matrix (ECM) components and 
between the ECM components and integrins can occur due to AGEs damage [10]. Plasma proteins 
affected by AGEs-precursors preferably bind to AGEs receptors (RAGES), leading to enhanced 
reactive oxygen species (ROS) production. Moreover, this cascade results in pathological gene 
expression trough the Nuclear Factor Kappa B (NF-κB), which enhances the AGEs-formation 
[11].  
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In case of chronic intracellular hyperglycaemia fructose-6-phosphate molecules are likely to shunt 
the glycolytic pathway through the hexosamine pathway. Via an enzymatic modification by 
glutamine—fructose-6-phosphate aminotransferase (GFAT), fructose-6-phosphate is turning into 
glucosamine-6-phosphate and then uridine diphosphate N-acetyl glucosamine. Modification in 
gene expression by this pathway results in increased production of transforming growth factor-β 
(TGF-β and) and plasminogen activator inhibitor-1 (PAI-1) [12].  
Furthermore, hyperglycaemia activates the protein kinase C (PKC) isoforms via elevating the 
intracellular diacyl-glycerol level. The hyperglycaemia induced PKC activation has several 
consequences on gene expression resulting in a plethora of pathological changes. The elevated 
level of the NAD(P)H oxidases enhances ROS activity, which activates further inflammatory 
cascades. Nevertheless, the NF-κB signalling plays a role in pro-inflammatory gene expression as 
well [13]. The increased TGF-β level results in capillary occlusion due to the higher amount of 
collagen and fibronectin in the vasculature [13]. In addition, the balance between the vasodilatory 
and vasoconstrictor factors is disturbed; the low endothelial nitric oxide synthase (eNOS) 
production is associated with concurrent overexpression of endothelin-1 (ET-1) [12, 14]. 
Furthermore, vascular permeability and angiogenesis are augmented due to the increased vascular 
endothelial grow factor (VEGF) level in smooth muscle cells [15]. Not only the endothelial cells 
and smooth muscle cells are affected by the PKC pathway, but the haemostasis is also disturbed 
via the elevated level of the PAI-1, resulting in decreased fibrinolysis [14]. 
All these mechanisms are interconnected, with numerous elements involved in more than one 
pathway (Fig 1.). The complex pathway networks in diabetes affect all organs in a very delicate 
way, connecting in several levels of action, enhancing its effects leading to endothelial and smooth 
muscle cell damage both on macro- and microvascular levels [16]. 
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Fig 1. Schematic figure of the activated pathophysiological pathways in hyperglycaemia 
Left: the main steps of the glycolysis, in the extracellular space pathophysiological pathways contributing 
to the diabetic complication. Right: the consequences of the activated pathways.  High intracellular 
glucose level activating the polyol pathway flux resulting in fructose overproduction. The fructose-6-
phosphate is shunting trough the hexosamine-pathway, while the higher amount of glicerin-aldehid-3-
phostphate resulting in PKC activation and AGE formation. This figure was made in BioRender. 
Abbreviations: NAD(P)H: Reduced nicotinamide adenine dinucleotide phosphate, GSSG: 
glutathione disulphide, GSH: reduced glutathione, GFAT: glutamine—fructose6-phosphate 
aminotransferase, UDPGlcNac: uridine diphosphate N-acetyl glucosamine:, DHAP: 
dihydroxyacetone phosphate, DAG: diacyl glycerol, PKC: protein kinase C, ROS: reactive oxygen 
species, AGEs: advanced glycation end products, RAGE: : advanced glycation end products 
receptor, eNOS: endothelial nitric oxide synthase, ET-1: Endothelin- 1, VEGF: vascular 
endothelial grow factor, TGF-β: of transforming growth factor-β, PAI-1: Plasminogen activator 
inhibitor-1, NF-κB: Nuclear Factor Kappa B IC: intracellular, ECM: extracellular matrix 
this figure was made in biorender 
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Multiorgan impairment in diabetes mellitus 
The persistent hyperglycaemia in diabetes leads to an excessive amount of micro and 
macrovascular complications and multiorgan damage. One of the most common complications is 
diabetic retinopathy, which may start to progress even seven years before the diagnosis in T2DM 
[17]. A further complication is the development of diabetic nephropathy, which can lead to renal 
failure and chronic kidney injury and manifests as microalbuminuria or proteinuria. Diabetic 
neuropathy has different forms; however, the most common is the chronic sensorimotor distal 
symmetric polyneuropathy [18]. As a macrovascular consequence, atherosclerosis develops, and 
diabetes increases the risk of cardiovascular diseases, such as coronary heart disease and 
myocardial infarction. Moreover, the consequences of long-term hyperglycaemia and diabetes 
may potentially harm the cerebral and respiratory function as well [19-22].  
Respiratory complications 
The pathophysiological consequences of diabetes may also damage the pulmonary epithelium, 
bronchial smooth muscle cells beyond the vascular damage. Thus, the lungs can be among the 
organs most affected morphologically and functionally by this disease [19-21, 23, 24]. It has been 
reported that lung function deterioration might happen even three years ahead of the diagnosis of 
diabetes [25]. However, the reported consequences of diabetes on the lung function are conflicting, 
and the mechanisms have not been fully characterised. Abundant pathophysiological changes 
might play an important role in respiratory damage, such as IR, leptin resistance, low-grade 
inflammation, microvascular damage and neuropathy.  
Long-term hyperglycaemia impairs the pulmonary vascular smooth muscle and endothelial cells 
resulting in elevated pulmonary vascular resistance, leading to decreased pulmonary blood flow 
and loss of pulmonary capillary blood volume [21]. Bronchial smooth muscle and pulmonary 
epithelial cells are affected by insulin resistance and low-grade inflammation [26] mostly via 
tumor necrosis factor α (TNF-α) activation and NF-κB signalling [27, 28]. The endothelial and 
epithelial dysfunction and ROS overproduction [29-31] contribute to the airway and lung 
parenchyma remodelling and alveolar wall thickening (79, 95). Furthermore, the altered pathways 
can manifest as sustained indirect and direct bronchial smooth muscle cell contraction [29, 30, 32, 
33].  
Since the lung is rich in elastin and collagen fibres, the ECM may also be a potential target for 
diabetes as alterations in the elastin–collagen matrix in the lung parenchyma [19, 34, 35] can occur. 
Thus, the above-detailed AGEs production and the AGEs-RAGES ligation might be abundant in 
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the lung. Type II pneumocyte damage results in decreased surfactant biosynthesis and secretion 
[36, 37] along with alveolocapillary barrier damage, thereby enhancing alveolar collapsibility and 
promoting lung derecruitment. Furthermore, leptin resistance might also contribute to respiratory 
complications through decreased alpha-1 antitrypsin and increased neutrophil elastase activity 
[38]. Diabetic autonomic neuropathy might also develop thus influencing the bronchomotor tone 
and airway responsiveness [39, 40] 
While the effects of diabetes on the lung have been evidenced by these previous investigations, 
diverging results have been reported on the potential alterations in the lung function in the presence 
of this disease. Some studies have demonstrated declines in spirometry outcomes [41-44], whereas 
others found no detectable changes [45-48]. Possible explanations for this discrepancy include the 
dependence of spirometry results on the effort and cooperation of patients [49, 50], and substantial 
differences between study populations, such as the type and severity of DM, age, and 
comorbidities. Furthermore, forced expiratory parameters have limited sensitivity to detecting 
detrimental changes in lung tissue and peripheral airway mechanics [23, 45, 48], the aspects of the 
lung affected primarily by DM [48, 51]. The effects of DM on the mechanical properties of the 
lung tissue has been studied in an ex vivo experiment, and the results were limited to assess the 
elastic behaviour of the lung parenchyma [52].  
Thus, it remains unclear how DM affects airway function and the viscoelastic mechanics of 
respiratory tissue, including its dissipative and elastic properties. It is also unknown whether DM 
influences the changes in mechanical parameters that occur with changes in lung volume. 
Cerebral complication 
The metabolic changes in diabetes deteriorate the brain function and structure insidiously in many 
ways, which can be attributed to the unique structure and physiology of the brain itself. Patients 
with diabetes have a higher risk of stroke (150-400%) with elevated stroke-related mortality [53] 
and the likelihood for dementia is around doubled [54]. The cerebral complications of diabetes 
have been studied intensively and they have led to clarification of several involved 
pathophysiological mechanisms. However, there is still lack of knowledge in fully understanding 
the cerebrovascular regulatory mechanism and consequences contributing to the organ failure. 
Cerebral autoregulation under physiological condition 
The brain has a high metabolic activity without energy reserve capacity and consumes about 20% 
of the total amount of oxygen available in the body. In addition, the brain depends on constant 
energy supply to meet the demand. Constant blood flow is required to maintain this fragile balance 
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[55]. Despite the physiological changes in systemic blood pressure, the cerebral blood flow is 
sustained by unique mechanisms such as the cerebrovascular autoregulation and the neurovascular 
coupling. Since the most powerful determinant of the flow in a vessel is its radius according to the 
Hagen-Poiseuille’s law, these mechanisms involve mainly harmonised vasoconstriction and 
vasodilatation to maintain constant blood flow. Nevertheless, changing in vascular resistance can 
modify cerebral blood flow rapidly in order to support regional and overall demands of brain 
circulation [56]. Under physiological conditions, cerebrovascular autoregulation is maintained in 
a relatively wide range of cerebral perfusion pressure (CPP). If the CPP exceeds 160 mmHg or 
drops lower than 60 mmHg, the cerebral blood flow remains fairly constant  [57]. 
In order to keep steady cerebral blood flow, vascular smooth muscle cells (VSMC) react against 
the different intramural pressures via myogenic response. Accordingly, the brain surface 
encompassed by the large pial arteries, and these arteries give nearly 50% of the total vascular 
resistance [58] compared to the vascular beds of other organs, where the myogenic response is 
determined by the small arteries [59, 60]. Nevertheless, studies describing that pial arteries respond 
to the negative feedback via the large-conductance calcium-activated potassium channels, but the 
penetrating arteries not. Interestingly, it was also reported that after ischemic insults myogenic 
dysfunction developed in the pial arteries [61] while the myogenic function of the penetrating 
arterioles remained intact [62].  
The other mechanism contributes to the maintenance the energy and oxygen balance of the 
metabolically active brain regions is the neurovascular coupling. Neurovascular coupling is a feed-
forward process where neuronal activation is translated to local vasodilation, called functional 
hyperaemia in the brain. Functional hyperaemia restores the depolarization-related lack of O2 and 
ATP and preserves normal neuronal function. [63-65]. This mechanism obliges tight interaction 
in the neurovascular unit, which is composed of vascular cells, neurons and astrocytes. Vascular 
cells include endothelial cells, pericytes and VSMCs in pial and parenchymal arterioles in order 
to communicate with neurons. However, at the capillary level only pericytes and endothelial cells 
take part in the neurovascular unit [66]. 
Molecular and structural changes in diabetes mellitus 
In diabetes, cerebral autoregulation might be impaired as a result of long term hyperglycaemia and 
compromised insulin signalling [67]. Increased cerebrovascular resistance and compromised 
blood flow occur due to the damaged myogenic response and dilatory mechanism. Endothelial 
dysfunction, morphological and functional changes are the key factors in impaired myogenic 
response. Intracellular hyperglycaemia induced polyol pathway and PKC activation resulting in 
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attenuated nitrogen monoxide (NO) release and increased ROS production. The decreased NO 
generation and biologic availability lead to further pro-inflammatory and inflammatory pathway 
activations. The decreased eNOS regulation is resulting in increased ET-1 production via TNF-α. 
[68-71]. Furthermore, the smooth muscle contraction might be prolonged and remarkable due to 
the phenotype changing of the VSMC [72] and the impaired Rho-associated protein kinase 
(ROCK) signal-induced increased myosin light-chain phosphorylation. [73-75].  
Moreover, the hyperpolarization ability of ATP-sensitive potassium channels (KATP) are reported 
to be compromised by hyperglycaemia, which can also elevate the myogenic tone [76].  As an 
adaptive response to the modified haemodynamic conditions and hyperglycaemia, arteriogenesis 
and vascular remodelling may occur. Several factors might contribute to vascular remodelling, 
such as PKC-activation or matrix metalloprotease upregulation [77], which alters the vessel 
diameter, wall thickness and vessel density. Phenotype-changing, hypertrophy and proliferation of 
the VSMCs together with pathologic collagen deposition, play an important role in the cerebral 
complication of diabetes [78]. Moreover, pathological vasoregression appears due to oxidative 
stress and endothelial dysfunction [79]. In addition, extracellular AGEs induce apoptosis through 
the transcription factor Forkhead box protein O1 via ROS activation [80].  
Diminished response to CO2 [81-83] and thickened intima layer were observed in diabetes [84] 
resulting in diminished cerebrovascular reactivity. Hence, impaired cerebrovascular 
autoregulation manifests not only as an elevated myogenic tone but a reduced ability to constrict 
[74]. Furthermore, diabetes destructs blood brain barrier (BBB) resulting in increased BBB 
permeability [85], pericyte loss [86], thereby compromising cerebrovascular integrity with 
neurovascular uncoupling.  
Since the brain is highly exposed to disturbances in the energy and oxygen supply, these 
pathophysiological changes can lead to a compromised oxygen balance in the cerebral tissue. 
Therefore, monitoring the changes in the regional oxygen balance in patients with diabetes may 
have particular importance.  Despite the well-established molecular and functional changes in 
diabetes, there is still lack of knowledge on the cerebral regional oxygen saturation (CrSO2), 
especially in anaesthetised patients in the perioperative period. Currently 30-40% of the patients 
undergoing cardiovascular surgeries have T2DM [87], which can partly be attributed to a therapeutic 
inertia in intensifying treatment of T2DM to reach optimal glycaemic, lipid and blood pressure 
control [88]. The structural and functional abnormalities in the vasculature [89] compromise 
adaptation mechanisms, subsequently increasing the risk of postoperative organ dysfunction, 
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including perioperative cerebral circulatory deficiency [90, 91]. The reduced vasodilatory reserve 
capacity increases the risk for a reduced cerebral tissue oxygen supply in T2DM patients, which 
may be responsible for the higher incidence of postoperative adverse neurocognitive dysfunction 
and stroke in the diabetic population [92-95]. Thus, it is particularly important to characterise the 
differences in CrSO2 between the diabetic and non-diabetic patient population and follow the 
changes in CrSO2 during the surgery. Moreover, in the perioperative period, the oxygen balance is 
routinely estimated from the oxygen saturation of central venous blood (ScvO2) [96]. However, 
ScvO2 reflects the overall oxygen balance [97]. Since substantial heterogeneity exists in oxygen 
extraction of various organs [98], the central venous oxygen saturation is not able to reflect 
regional changes of the tissue oxygenation.  
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HYPOTHESIS AND AIMS 
The general aim of the present thesis was to extend our knowledge on the effect of diabetes on two 
distinct vital organs, the lung, and the brain in translational and clinical scenarios. A randomised 
controlled experimental study was performed to characterise the pulmonary effects of diabetes. 
This study design offered ideal conditions to reveal the adverse pulmonary mechanical 
consequences of diabetes without other confounding factors, such as the onset of the disease, age 
or comorbidities. Furthermore, well-controlled interventions with great translational value were 
feasible in this experimental model allowing the assessment of the volume-dependent behaviour 
of the lungs and the lung responsiveness in diabetes. The second study enclosed in the present 
thesis focused on the cerebral effect of diabetes in human subjects. Monitoring the regional 
differences in the tissue oxygen saturation is essential in a patient population with potentially 
compromised macro- and microcirculation, especially in the perioperative period. Since the 
cerebral circulation is disturbed in diabetes. and the brain is at risk of energy and oxygen supply 
deficit, we aimed at characterising the CrSO2 in anaesthetised mechanically ventilated patients 
with diabetes during cardiac surgery. 
Effect of diabetes on respiratory function: experimental study 
The impact of diabetes on respiratory function has not yet been completely characterised. Changes 
in airway function and in the viscoelastic mechanical properties of the respiratory tissue remain 
unclear. Lack of knowledge continues to exist in the alterations of the airway and respiratory tissue 
mechanical parameters subsequent to changes in lung volume. Therefore, our aims in this study 
were to elucidate the effects of long-term hyperglycaemia on the respiratory system. Thus, we 
investigated the changes in the airway and respiratory tissue viscoelastic parameters with 
measurement techniques that allowed the exact characterization of these changes in well-
established animal models of T1DM and T2DM. To address this aim, the following hypotheses 
were tested on the bases of theoretical considerations and previous findings:  
I. Since the magnitude of the insults varies in the two groups with diabetes, we 
hypothesise differences in the respiratory outcomes between the type1 and type2 DM 
groups. 
II. Deteriorations develop both in the dissipative and elastic components of respiratory 
tissue viscoelasticity. 
III. The deteriorated airway function in diabetes results in changes in the airway 
responsiveness.  
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IV. The detrimental changes in respiratory function in T1DM and T2DM affect their 
changes with lung volume. 
V. DM-induced functional and structural changes in the respiratory system are expected 
to result in loss of the lung volume, compromised gas exchange, and histological 
alteration. Thus, we investigated the functional residual capacity (FRC), fraction of 
arterial partial pressure of oxygen to the inspired fraction of oxygen (PaO2/FiO2), 
intrapulmonary shunt (Qs/Qt) and the amount of collagen in lung tissue samples. 
Effects of diabetes on cerebral integrity: clinical study 
The oxygen extraction rate of cerebral tissue is one of the highest in the body under physiological 
conditions [98], and substantial heterogeneity exists in oxygen extraction of various organs [98]. 
Therefore, the mixed venous oxygen saturation might not able to reflect regional changes in the 
tissue oxygenation and the cerebral tissue oxygen saturation derived from ScvO2 can be 
overestimated [99]. Diabetic complications may compromise the cerebral tissue oxygen balance 
[100] and thus, estimation the intraoperative brain tissue oxygenation is particularly challenged in 
diabetic patients. Therefore, online monitoring of regional cerebral tissue oxygen saturation 
(CrSO2) would have an advantage in T2DM patients in the intraoperative period to reveal 
hypoxemic episodes in the brain.  
I. We hypothesise that the initial CrSO2 measured by NIRS differs between patients with 
and without diabetes.  
II. We hypothesise that the gap between ScvO2 and CrSO2 (gSO2) is significantly widened 
in T2DM patients as a cardiovascular consequence of diabetes. Accordingly, ScvO2 is 
not suitable to infer CrSO2 in diabetic patients. To test this hypothesis, we aimed at 
comparing direct measurements of CrSO2 using near-infrared spectroscopy (NIRS) to 
simultaneously obtained ScvO2 data in patients with and without T2DM.  
III. ScvO2, CrSO2 and gSO2 are expected to exhibit intraoperative changes during cardiac 
surgery depending on the patient management with or without cardiopulmonary bypass 
(CPB). Thus, measurements were made during anaesthesia in two groups of cardiac 
surgery patients with or and without T2DM: those undergoing CPB and those 
scheduled for off-pump coronary artery bypass (OPCAB) grafting procedure.
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MATERIALS AND METHODS 
Methods in the experimental study 
Ethics 
This study was approved by the National Food Chain Safety and Animal Health Directorate of 
Csongrád County, Hungary (no. XXXII./2098/2018), on September 24, 2018. The procedures 
were implemented in compliance with the guidelines of the Scientific Committee of Animal 
Experimentation of the Hungarian Academy of Sciences (updated Law and Regulations on Animal 
Protection: 40/2013. [II. 14.], the Government of Hungary), and European Union Directive 
2010/63/EU on the protection of animals used for scientific purposes. The results were reported in 
line with the ARRIVE guidelines. 
Inducing diabetes 
The study used 5-week-old male Wistar rats (mean weight ± 95% confidence interval, 187.3 ± 
3.7 g, n = 42). During the initial phase of the study protocol, the animals were housed for 15 weeks 
under close daily observation in accordance with the animal welfare assessment and 3R guidelines. 
Well-validated models were adapted to induce models of type 1 and type 2 DM, with proven 
hyperglycaemia, insulin resistance, and the diffuse degeneration of pancreatic cells [101-106]. The 
5-week-old rats were assigned randomly to three protocol groups: model of type 1 DM (DM1 
group, n = 14), model of type 2 DM (DM2 group, n = 14), and control group (n = 14). They were 
fed in accordance with their group allocations (Fig 2): rats in the DM1 and control groups received 
a normal diet (fat and protein contents of 3.9% and 20.1%, respectively), whereas those allocated 
to the DM2 group were fed a high-fat diet (Altromin C1080, 47% fat, 18% protein, 35% 
carbohydrate; Altromin Spezialfutter GmbH & Co. KG, Lage, Germany). After a 3-week period 
(at the age of 8 weeks), the DM1 group rats were treated with a single high dose of streptozotocin 
(STZ, 65 mg/kg) [101, 105], the DM2 group rats were treated with a low dose (30 mg/kg) of STZ 
[102-104, 106], and the controls received the vehicle of the STZ (citrate buffer, pH 4.4). Before 
the injection of STZ or vehicle and 1 week after the treatment (age of 9 weeks), fasting glucose 
levels were measured from the tail vein using an Accu-Chek Active blood glucose meter (Roche, 
Basel, Switzerland). Four rats in the DM2 group were administered a second injection of 30 mg/kg 
STZ treatment because their fasting glucose level was <7.8 mmol/l [103, 106]. One animal in the 
DM1 group was sacrificed after 7 weeks due to isolation and its unsatisfactory health condition. 
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Animal preparations 
The experiments were performed on week 16 (age of 20 weeks). Anaesthesia was induced by an 
intraperitoneal injection of sodium pentobarbital (45 mg/kg, Sigma-Aldrich, Budapest, Hungary). 
After administering local anaesthesia (subcutaneous lidocaine, 2–4 mg/kg), a polyethylene 
cannula with an inner diameter of 18G was inserted into the trachea through a tracheostomy. The 
tracheal cannula was connected to a small animal ventilator (Model 683; Harvard Apparatus, South 
Natick, MA, USA), and the animal was mechanically ventilated (55-60 breaths/min, tidal volume 
7 ml/kg, with a fraction of inspired oxygen [FiO2] of 21%). The femoral artery was catheterised 
for blood pressure measurements and the collection of blood samples. The femoral vein was 
cannulated for drug administration and the jugular vein was secured for drug administration and 
the collection of venous blood samples. Anaesthesia was maintained with pentobarbital (5 mg/kg, 
intravenous (iv.), every 30 min). The rat was placed on a heating pad (model 507223F; Harvard 
Apparatus, Holliston, MA, USA) and its body temperature was maintained at 37 ± 0.5 °C. The 
forced oscillation measurements to evaluate the impedance of the respiratory system were made 
under neuromuscular blockade, achieved by the repeated iv. administration of pipecuronium 
(0.1 mg/kg every 30 min; Arduan, Richter-Gedeon, Budapest, Hungary).  
Figure 2: Scheme summarizing the treatment Three groups of animals received different treatments 
according to their group allocations. The animals in DM1 and in C groups received normal diet, while the 
rats in the DM2 group were fed with high-fat diet. After the three-week pretreatment period animals in the 
DM1 group received high-dose intraperitoneal streptozotocin. Rats in the DM2 group received low dose 
streptozotocin. Abbreviations: DM1: model of type 1 diabetes, DM2: model of type 2 diabetes, C: control 
group; STZ: streptozotocin in mg/kg 
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Measurement of functional residual capacity 
The FRC was measured as described previously [107]. Briefly, the rat was tracheostomised and 
placed in a whole-body plethysmography box (Fig 3.). The trachea and box were closed at end-
expiration and the measurements were made while the animal generated breathing efforts against 
the closed trachea. The FRC was calculated from the simultaneously measured tracheal and box 
pressure signals by applying the Boyle–Mariotte law [107].  
Measuring airway and respiratory tissue mechanics 
The input impedance of the respiratory system (Zrs) was measured by the forced oscillation 
technique, as described previously [108]. Briefly, the tracheal cannula was connected to a 
loudspeaker-in-box system, while ventilation was suspended at end-expiration. A small-amplitude 
pseudorandom signal (<1.5 cmH2O, with 23 non-integer multiple-frequency components between 
0.5 and 20.75 Hz) was applied to the tracheal cannula through a wave tube (polyethylene; length 
100 cm, internal diameter 2 mm). To maintain uniform transpulmonary pressure during the 
measurements, the pressure in the loudspeaker box was set to be equivalent to that of the positive 
end-expiratory pressure (PEEP) used for that experiment (0, 3, or 6 cmH2O). During 8-s 
measurement periods, pressures were measured simultaneously at the loudspeaker and tracheal 
ends of the wave tube with miniature differential pressure transducers (Honeywell Differential 
Pressure Sensor model 24PCEFA6D; Honeywell, Charlotte, NC, USA). Zrs was calculated as the 
load impedance of the wave tube [108]. At least four technically acceptable measurements were 
made at each stage of the protocol. The mechanical properties of the respiratory system were 
characterised by fitting a well-validated model [109] to the averaged Zrs spectra. The model 
comprised frequency-independent airway resistance (Raw) and airway inertance in series with a 
viscoelastic constant-phase tissue unit [109], and incorporated tissue damping (G) and elastance 
Figure 3.  Scheme of the measurement apparatus for the assessment of the functional residual capacity. 
Ptrachea and Pbox indicate the pressure sensors at the tracheal canula and at the whole-body plethysmography 
box, respectively. 
. 
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(H). Tissue histeresivity (), which characterises the coupling between the dissipative and elastic 
forces within the respiratory tissues was calculated as G/H [110].  
 
Measurement of intrapulmonary shunt fraction and oxygenation 
For the blood gas analyses, 0.1-ml samples of arterial and central venous blood were collected 
simultaneously. The capillary (CcO2), arterial (CaO2), and venous (CvO2) oxygen contents were 
evaluated from the blood gases and used to calculate the intrapulmonary shunt fraction (Qs/Qt) by 
applying the modified Berggren equation [111]:  
𝑄𝑠
𝑄𝑡
=
𝐶𝑐𝑂2 − 𝐶𝑎𝑂2
𝐶𝑐𝑂2 − 𝐶𝑣𝑂2
 
To characterise the oxygenation efficiency PaO2/FiO2 was calculated from the arterial blood gas 
assessments. 
Lung tissue histology 
After completing the experimental protocol, a midline thoracotomy was performed, and the lungs 
were fixed by introducing 4% formaldehyde via the tracheal cannula with a hydrostatic pressure 
of 20 cmH2O. The heart-lung blocks were then removed in one piece from the thoracic cavity. To 
visualise the collagen in the lung, tissue samples were fixed in 4% buffered formalin, embedded 
in paraffin, and 5-m tissue sections were stained with Picro Sirius Red staining (Sigma-Aldrich). 
These were scanned with a Zeiss Mirax MIDI slide scanner at a magnification of ×20. At least 
Figure 4.  Scheme of the forced oscillatory measurement apparatus  
P1 and P2 indicate the miniature pressure sensors at the loudspeaker and at the tracheal end of the wave tube, 
respectively. During the measurements, the respiratory limb was closed, and the animal was connected to the 
loudspeaker via the wave tube. Between the measurements oscillatory circuit was closed and the respiratory 
limb was open. The Erlenmeyer flask filled with water was used to generate PEEP  
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three representative 0.15-mm2 sized rectangular regions of interest that contained alveoli without 
bronchi or large vessels were analysed in each section. The collagen was segmented and quantified 
in the lung tissue sections by using the Trainable Weka Segmentation plugin in Fiji software [112]. 
The histological analyses were made by one person who was blinded for the group allocation. 
Experimental protocol 
collThe experimental protocol is summarised in Fig 5. Following a 12-week housing period after 
the induction of DM (at the age of 20 weeks), each rat was anesthetised, and the trachea was 
secured. The FRC was measured, followed by the surgical insertion of the arterial and venous 
catheters. Animals were initially ventilated with a PEEP of 3 cmH2O. A hyperinflation manoeuvre 
was then performed to standardise the volume history. After 3 min, arterial and venous blood gas 
samples were taken simultaneously and the first set of set of Zrs were collected. Blood gas analyses 
and Zrs measurements were made at PEEP levels of 0 and 6 cmH2O, in random order. A period 
of 3 min was allowed for the animal after each PEEP step to maintain a steady state condition during 
the data collection. After completing the study on characterizing the PEEP-dependence, the PEEP 
was fixed at 3 cmH2O and a set of Zrs data was collected to establish the baseline for the 
bronchoprovocation tests with doubling doses (2, 4, 8, 16, and 32 µg/kg/min) of iv methacholine 
(MCh). At each MCh dose, steady-state bronchoconstriction was established (defined as <5% 
difference in Raw between consecutive measurements) and forced oscillation Zrs data were 
measured. After completing the measurement protocol, each animal was euthanised by an 
overdose of pentobarbital and the lungs were removed for histological analysis. 
Figure 5. Schemes summarizing the experimental protocol (B). After 12 weeks, forced oscillation 
measurements and blood gas analyzes were performed at three different positive end-expiratory pressures 
(0, 3, and 6 cmH2O: PEEP0, PEEP3, and PEEP6, respectively). Forced oscillation respiratory mechanics 
were assessed at a PEEP of 3 cmH2O during provocation tests with increasing doses (2-32 g/kg/min) of 
methacholine (MCh) following the baseline measurement (BL). Further abbreviations: FRC: measurement 
of functional residual capacity, PREP: animal preparations 
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Methods in the clinical study 
Patients 
Hundred thirty-nine consecutive patients with T2DM (n=48) and control (C) subjects without 
T2DM (n=91) undergoing cardiac surgery were enrolled in this prospective descriptive cohort 
study. Patients were defined as having T2DM if their medical history included a diagnosis of 
T2DM and haemoglobin A1c (HbA1c) > 6.4%. All patients underwent either OPCAB (C-
OPCAB, n=31 and T2DM-OPCAB, n=24) or CPB (C-CPB, n=60, T2DM-CPB, n=24). Patients 
older than 80 years of age or with poor ejection fraction (<40%), unilateral internal carotid stenosis 
(>75%), or medical history of smoking, chronic obstructive pulmonary disease or stroke were 
excluded from the study. The protocol was approved by the Human Research Ethics Committee 
of Szeged University, Hungary (no. WHO 2788), and the patients gave their informed consent to 
participation in the study. The study was performed in accordance with the ethical standards laid 
down in the 1964 Declaration of Helsinki and its later amendments. 
Anaesthesia 
One hour before the surgery, patients were premedicated with lorazepam (per os, 2.5 mg). Before 
induction of anaesthesia, the NIRS sensors (INVOS 3100, Somanetics, MI, USA) were positioned 
on both sides of the forehead. Sensors to detect depth of anaesthesia were also mounted on the 
forehead to monitor EMG and EEG activities. These signals were used to calculate response (RE) 
and state entropy (SE), respectively (GE Healthcare, Chicago, USA). Induction of anaesthesia was 
achieved by iv midazolam (30 μg/kg), sufentanil (0.4–0.5 μg/kg), and propofol (0.3–0.5 mg/kg), 
and iv propofol (50 µg/kg/min) was administered to maintain anaesthesia. Intravenous boluses of 
rocuronium (0.6 mg/kg for induction and 0.2 mg/kg every 30 minutes for maintenance) was 
administered iv to ensure neuromuscular blockade. A cuffed tracheal tube (internal diameter of 7, 
8, or 9 mm) was used for tracheal intubation, and patients were mechanically ventilated (Dräger 
Zeus, Lübeck, Germany) in volume-controlled mode with decelerating flow. A tidal volume of 7 
ml/kg and a positive end-expiratory pressure of 4 cmH2O were applied, and the ventilation 
frequency was adjusted to 12–14 breaths/min to maintain end-tidal CO2 partial pressure of 
36-38 mmHg. Mechanical ventilation was performed with a fraction of inspired oxygen of 0.5 
during the entire OPCAB procedure and before CPB, and it was increased to 0.8 after CPB. As a 
standard part of the cardiac anaesthesia procedure, oesophageal and rectal temperature probes were 
introduced, and a central venous line was inserted into the right jugular vein. The left radial artery 
was also cannulated to monitor systolic, diastolic and mean arterial (MAP) blood pressures and 
arterial blood gas samples.  
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The membrane oxygenator was primed with 1,500 ml lactated Ringer’s solution prior to CPB. 
Intravenous heparin (150 or 300 U/kg for OPCAB and CPB procedures, respectively) was injected 
into the patient, and an activated clotting time of 300 s was achieved during OPCAB and of 400 s 
during CPB procedures. During CPB, mild hypothermia was allowed, the mechanical ventilation 
was stopped, and the ventilator was disconnected without applying positive airway pressure. 
Before restoring ventilation, the lungs were inflated 3–5 times to a peak airway pressure of 30 
cmH2O to facilitate lung recruitment. Normothermia was maintained in the OPCAB patients. 
Measurement of cerebral-tissue oxygen saturation  
The spatially resolved continuous-wave NIRS technique was applied to estimate CrSO2. This 
monitor uses two different wavelengths (730 and 810 nm) and has two detectors positioned 3 and 
4 cm from the light source. Computing the differences between the intensity of the emitted and the 
reflected light [113] with two receivers [114] allows the measurement of the oxygen saturation of 
the cerebral cortex. In this study, two adult sensors were applied on the left and right sides of the 
patient’s forehead symmetrically, placed more than 3 cm from the superior rim of the orbit 
[115].The cerebral-tissue oxygen saturation was monitored continuously during the surgical 
procedures and the data were registered in each protocol stage. The mean value of the CrSO2 
measured by the sensors was calculated for each protocol stage and used for further analyses. 
Measurement of central venous oxygen saturation 
The ScvO2 was measured from central venous blood samples (Radiometer ABL 505, Copenhagen, 
Denmark). The proper positioning of the central venous catheter was verified by the surgeon via 
manually palpating the catheter tip. The partial pressures of oxygen (PaO2) and carbon-dioxide 
(PaCO2), haemoglobin, pH and oxygen content (CaO2) were determined from arterial blood gas 
samples at each protocol stage. 
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Measurement protocol 
The scheme of the measurement protocol is outlined on Fig 5. After securing arterial and peripheral 
venous lines and placement of NIRS and entropy sensors, data collection was initiated immediately 
before anaesthesia induction in all groups of patients. Since catheterization of the jugular vein was 
scheduled after anaesthesia induction, ScvO2 and gSO2 data were not available at the first protocol 
stage. After anaesthesia induction and muscle relaxation, all measurements were repeated before 
surgical incision. For the patients undergoing CPB procedures, the whole data set was registered 
at the beginning of CPB after clamping the aorta and 5 min before the end of CPB. For the patients 
undergoing OPCAB procedures, collection of the full set of data was performed during 
performance of the first proximal anastomosis between the aorta and saphenous vein graft. The 
final stage of the protocol was allocated to the end of the operation after sternal closure. All 
invasive (i.e. arterial and venous blood gas) and non-invasive data were registered simultaneously 
at each protocol stage after ensuring a 3 min stead-state condition.  
 
Figure 6. The scheme of the measurement protocol. Measurements were made at five time points in the 
patients with cardiac surgeries requiring cardiopulmonary bypass (Groups C-CPB and T2DM-CPB), 
while four measurements were performed in the patients with off-pump coronary bypass grafting 
surgeries (C-OPCAB and T2DM-OPCAB). Cerebral tissue oxygen saturation (CrSO2) measured by 
near infrared spectroscopy (NIRS). Central venous oxygen saturation (ScvO2) determined from blood 
gas analyses (BG). 
 
25 
 
Statistical analyses 
In the animal study, data are expressed as mean ± standard deviation (SD) for normally distributed 
variables, and median with interquartile range (1st - 3rd quartile) otherwise. The Kolmogorov–
Smirnov test was used to test data distributions for normality; where necessary, a logarithmic 
transformation was performed to normalise the data. Two-way repeated-measures analysis of 
variance (ANOVA) with Holm–Sidak post hoc analyses were used to assess the effects of the 
PEEP and group allocation on the respiratory mechanical and oxygenation parameters. Between 
group differences in airway responsiveness to MCh were evaluated with further two-way repeated-
measures ANOVA with Holm–Sidak post hoc analyses. The MCh doses that elicited a 50% 
increase in Raw relative to baseline (PD50) were determined by fitting linear models to the 
individual dose–response curves. One-way ANOVA with Dunn’s post hoc analyses was used to 
evaluate the differences between groups in body weights, blood glucose levels, specific airway 
and respiratory tissue parameters, PD50, and the results of the histological analysis. Correlation 
between the collagen expression in the lung tissue and viscoelastic properties of the respiratory 
system was determined by the Pearson correlation analysis.  
In the clinical study for numerically reported data, the scatters in measured variables are expressed 
as 95% confidence interval for the mean. The normality of the data was verified with the Shapiro-
Wilk test; one-way analysis of variance (ANOVA) was used to test differences in the demographic, 
anthropometric, and clinical characteristics of the patients when they were included in the control, 
and diabetic groups. Fisher’s exact test was performed to assess the differences in the surgical 
procedures between the protocol groups. Pearson’s correlation test was applied to assess the 
relationship between global and regional oxygen saturation indices. Two-way repeated measures 
ANOVA with the inclusion of an interaction term was used for all measured variables with the 
protocol stage as within-subject factor (protocol stages) and group allocation as between-subject 
factor to establish the effects of T2DM and the surgical procedure on the oxygen saturation indices. 
The Holm–Sidak multiple comparison procedure was adopted to compare the variables in the 
study groups at different protocol stages. Further two-way repeated measures ANOVA tests were 
applied to assess between-group and within-group differences in the parameters influencing 
cerebral-tissue oxygen saturation.  
Sample size estimations were performed for both studies. In the experimental study the sample 
size estimation for the repeated-measures ANOVA for the variable Raw, with a power of 0.8 and 
alpha of 0.05. indicated that at least 10 animals were required in each group to detect a statistically 
significant difference [116]. In the clinical study sample sizes were estimated to enable the 
detection of a 10% difference in the primary outcome parameter gSO2 that we considered clinically 
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significant. Accordingly, sample-size estimation based on an ANOVA test with four groups of 
patients indicated that 24 patients were required in each group to detect a significant difference 
between the protocol groups (the assumed variability of 10%, power of 0.8 and alpha of 0.05). 
Due to the prevalence of T2DM in cardiac surgery, this targeted number of T2DM patients resulted 
in twofold number of the patients without diabetes.  
The statistical tests were performed with the SigmaPlot statistical software package (Version 13, 
Systat Software, Inc., Chicago, IL, USA) and R environment. All reported p values are two-sided, 
and the statistical tests were performed with a significance level of p < 0.05. 
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RESULTS 
Effects of diabetes on the respiratory system: results in the experimental study  
Initial parameters after the treatment period 
Body weights, serum glucose levels, and the initial lung function parameters for the control and 
STZ-treated rats are summarised in Table 1. At the end of the 12-week treatment period, the mean 
body weight in the rats of the DM1 group was significantly lower than those in the DM2 and 
control groups. Significant elevations in blood glucose level were observed in the rats of the DM1 
and DM2 groups compared to the control animals. The FRC measurements showed a significant 
reduction in static lung volume in the DM1 group rats; however, when the FRC values were 
normalised to body weight, they were significantly higher for the DM1 group rats than for those 
in the other two groups. Specific airway and respiratory tissue parameters were significantly higher 
in the DM1 and DM2 groups than in the control group. 
 Group C 
(n=14) 
Group DM1 
(N=13) 
Group DM2 
(N=14) 
p 
Body weight (g) 563±49 348±91* 529±76# <0.001 
Blood glucose (mmol/l) 5.8 (5.6-6.1) 29.9(25.75-35)* 14.75(7.0-27.3)* <0.001 
FRC (ml) 4.3±0.5 3.6±0.6* 4.4±0.8# 0.003 
FRCN (ml/kg) 7.5(6.8-8.7) 10.2 (8.6-11.3)* 8.1(6.7-9.3)# 0.003 
SRaw (cmH2O.s) 0.23(0.19-0.24) 0.27(0.24-0.32)* 0.27(0.23-0.34)* 0.004 
SG (cmH2O) 3.1(2.7-3.3) 3.4(3.2-4.0)* 3.6(3.0-4.4)* 0.023 
SH (cmH2O) 12.0±2.7 17.3±4.9* 17.2±5.8* 0.007 
Table 1. Main outcome parameters: In the control rats (Group C) and in model of type 1 (Group DM1) 
and type 2 (Group DM2) diabetes mellitus presented as mean±SD (Body weight, FRC and SH) and median 
(Q1,Q3), (Blood glucose, FRCN, SRaw, SG) . FRC: functional residual capacity, FRCN: functional residual 
capacity normalised to body weight (FRC/BW), SRaw: specific airway resistance (Raw × FRC), 
SG: specific respiratory tissue damping (G × FRC), SH: specific airway resistance (H × FRC); all 
obtained without applying positive end-expiratory pressure. p: results of the one-way ANOVA tests and 
ANOVA on ranks. *: p<0.05 vs. Group C, #: p<0.05 between Groups DM2 and DM1 by using Dunn's post-
hoc analyses. 
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Changes in the respiratory mechanical properties 
Fig 7 shows how the airway and viscoelastic parameters of the respiratory tissues varied with the 
PEEP for the three groups. Raw was significantly greater in both groups of diabetic animals than 
in the control group at all PEEP levels (p < 0.001). Two-way ANOVAs showed significant 
interactions between group and PEEP level for the parameters G (p < 0.001) and H (p < 0.001), 
indicating that the treatment affected these parameters’ dependence on PEEP. The dissipative 
properties of the respiratory tissues reflected by G were significantly compromised in the DM1 
group when PEEP = 0 cmH2O. The respiratory tissue stiffness was elevated in both the DM1 
(p < 0.001) and the DM2 (p = 0.039) groups at all PEEP levels, with more pronounced differences 
at low lung volumes. The dissociated PEEP dependences of G and H resulted in changes in  that 
varied between the groups, with significant decreases observed in the DM1 group for all three 
levels of PEEP (p < 0.001) and in the DM2 group when the PEEP was 3 or 6 cmH2O (p = 0.014) 
compared to the control group.  
Figure 7. Airway and viscoelastic respiratory tissue mechanical parameters. Measurements obtained at 
positive end-expiratory pressures of 0, 3, and 6 cmH2O (PEEP0, PEEP3, and PEEP6, respectively) in 
control rats (closed circles, C, n = 14) and in rats in the type 1 diabetes (DM1, open squares, n = 13) and 
type 2 diabetes (DM2, open triangles, n = 14) groups. The symbols and error bars represent the mean and 
SD values, respectively. * p < 0.05 vs. PEEP0 within a group; † p < 0.05 vs. PEEP3; # p < 0.05 vs. C 
within a PEEP. Abbreviations: Raw, airway resistance; G, tissue damping (resistance); H, tissue elastance; 
, tissue histeresivity η= G/H. C within a condition; † p < 0.05 vs. DM2 within a condition. 
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Airway response to Metacholine 
Airway resistance and its absolute (right) and relative (left) changes to the baseline (BL) during 
the MCh provocation tests are shown in Fig 8. Significant elevations in the basal Raw values were 
observed in the DM1 (p<0.001) and DM2 (p<0.05) groups. These differences remained at the 
lower doses of MCh, whereas the absolute value of Raw became significantly lower in the DM1 
rats at the highest dose of MCh (p<0.05). Due to the significantly higher baseline Raw values in 
the diabetic rats, the differences in the dose-response curves to MCh between the protocol groups 
is more obvious when the responses are expressed as relative changes to baseline (right). In the 
control and DM2 groups, elevations in Raw were statistically significant from the 8 µg/kg/min 
MCh dose (p < 0.05), whereas in the DM1 group this increase was only observed after 16 
µg/kg/min (p < 0.05). At the highest MCh dose, the MCh-induced relative increases in Raw were 
significantly lower in both DM1 and DM2 groups compared to control (p = 0.001). The 
characteristic shifts in the dose-response curves showed that the PD50 for MCh was significantly 
higher for the DM1 group (25.3 ± 20 µg/kg/min) than for the control group (8.9 ± 3.3 µg/kg/min, 
p = 0.001) and the DM2 group (12.7 ± 7.4 µg/kg/min, p = 0.026).  
 
  
Figure 8. Airway resistance and its absolute (right) and relative (left) changes to the baseline during the 
methacholine provocation tests in control rats (closed circles, C, n = 14), in rats in the type 1 diabetes (DM1, 
open squares, n = 13) and type 2 diabetes (DM2, open triangles, n = 14) groups. The symbols and error 
bars represent the mean and SD values, respectively. * p < 0.05 vs. BL within a group; # p < 0.05 vs. C 
within a condition; † p < 0.05 vs. DM2 within a condition 
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The effect of PEEP applying on the gas exchange parameters 
The parameters reflecting the gas exchange properties of the lungs are summarised in Fig 9. The 
rats with healthy lungs in the control group exhibited moderate values of intrapulmonary shunt 
(<9.3%) and physiological PaO2/FiO2 (>438 mmHg); these indices exhibited systematic 
improvements with increasing PEEP to 3 (p < 0.02) and 6 cmH2O (p < 0.05). In the DM2 group, 
there was a near-significant tendency for Qs/Qt to be reduced compared to the control group at a 
PEEP of 6 cmH2O (p = 0.065), whereas PaO2/FiO2 was reduced at a PEEP of 3 cmH2O (p = 0.05) 
and tended to diminish at a PEEP of 6 cmH2O (p = 0.069). In the DM1 group at all three PEEP 
levels, there were significant increases in the intrapulmonary shunt (p < 0.001) associated with 
markedly compromised PaO2/FiO2 (p < 0.001). In addition, changes in the PEEP dependence of 
the gas exchange parameters were observed in the DM1 group, with no monotonous improvements 
in Qs/Qt and PaO2/FiO2 with increasing PEEP. 
 
Figure 9. Measurements obtained at positive end-expiratory pressures of 0, 3, and 6 cmH2O (PEEP0, 
PEEP3, and PEEP6, respectively) in control rats (closed circles, C, n = 14) and in rats in the type 1 
diabetes (DM1, open squares, n = 13) and type 2 diabetes (DM2, open triangles, n = 14) groups. The 
symbols and error bars represent the mean and SD values, respectively. * p < 0.05 vs. PEEP0 within a 
group; # p < 0.05 vs. C within a PEEP; † p < 0.05 vs. DM2 within a PEEP. 
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Histological consequences 
Fig 10. shows the expression of collagen in the three groups. The percentage area of collagen was 
significantly higher in both DM groups than in the control group (p < 0.001). The collagen content 
of the lung parenchyma was greater in the DM1 group than in the DM2 group (p < 0.001). 
Figure 10. Collagen expression in the rat lungs. Areas of collagen obtained from lung histology (left) and 
representative lung tissue sections (right) in control rats (C, n = 14) and in rats in the type 1 diabetes 
(DM1, n = 13) and type 2 diabetes (DM2, n = 14) groups. * p < 0.05 vs. C; # p < 0.05 vs. DM1. 
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Fig 11. shows the relationship between the percentage area of collagen obtained by lung histology 
and the viscoelastic dissipative and elastic mechanical parameters. There were significant 
correlations between the histology and both tissue mechanical indices, G and H. 
 
Figure 11. Correlation between the collagen and the viscoelastic parameters of the rat lungs. 
Correlations between the percentage areas of collagen obtained by lung histology and forced oscillation 
mechanical parameters for tissue damping (G) and elastance (H) in control rats (C, n = 14) and in rats in 
the type 1 diabetes (DM1, n = 13) and type 2 diabetes (DM2, n = 14) groups. The solid line indicates the 
linear regression curve.
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Effects of diabetes on the cerebral integrity: results in the clinical study  
Patient characteristics 
Table 2 summarises the demographic, anthropometric and clinical characteristics and surgical 
procedures of the patients with and without T2DM. HbA1c was significantly higher in diabetic 
patients while there was no significant difference in the other parameters (i.e. weight, height, age 
or ejection fraction). 
 
Table 2: Patient characteristics, surgical procedures and diagnoses (in parentheses) 
HbA1c: Hemoglobin-A1c, ARR: aortic root replacement, AAA: aortic arch reconstruction; AVR: aortic 
valve replacement to repair aortic stenosis (AS) or aortic insufficiency (AI); MVR/P: mitral valve 
replacement/plasty; CABG: coronary artery bypass grafting; MI: mitral insufficiency; LA: left atrium, 
CAD: coronary artery disease. Data for preoperative parameters are shown as mean and 95% confidence 
interval for the mean; data for surgical procedures and diagnoses are represented as number of patients. 
  Group C (n=91) 
Group T2DM 
(n=48) 
p 
P
re
o
p
er
a
ti
v
e 
p
a
ra
m
e
te
rs
 Weight (kg) 83 (79-86) 83 (77-89) 0.97 
Height (cm) 168 (166-170) 165 (163-168) 0.20 
Age (years) 65 (63-68) 68 (67-70) 0.30 
Ejection fraction (%) 60 (56-64) 56 (51-61) 0.15 
HbA1c (%) 5.6 (5.4-5.7) 7.2 (6.7-7.7) <0.001 
Duration of T2DM (years) - 11 (9-13) - 
S
u
rg
ic
a
l 
p
ro
ce
d
u
re
s 
a
n
d
 d
ia
g
n
o
se
s 
ARR (AAA) (n) 1 0 1.00 
AVR (AS) (n) 28 9 0.15 
AVR (AI) (n) 1 1 1.00 
AVR+MVR (AS+MI) (n) 2 3 0.33 
AVR+CABG (AS) (n) 11 3 0.37 
AVR+CABG (AI) (n) 3 2 1.00 
MVR/P (MI) (n) 10 4 0.77 
MVR+CABG (MI+CAD) (n) 3 1 1.00 
OPCAB (CAD) (n) 31 24 0.07 
LA Myxoma (n) 1 1 1.00 
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Serum glucose level, CrSO2 and parameters determining tissue oxygen balance obtained before 
anaesthesia induction are demonstrated on Table 3. The serum glucose level was higher and the 
CrSO2 values were lower in the T2DM patients as compared to the control patients. Evidence for 
a difference in parameters determining the oxygen supply was only observed in haemoglobin 
concentration and CaO2. Response entropy, state entropy and oesophageal temperature did not 
differ between the protocol groups. 
 Group C (n=91) Group T2DM (n=48) p 
Glucose (mmol/L) 5.9 (5.7-6.0) 8.04 (7.2-8.9) <0.001 
CrSO2 (%) 68 (66-69) 60 (58-63) <0.001 
MAP (mmHg) 88 (86-90) 86 (83-90) 0.29 
CaO2 (ml/dl) 17.0 (16.4-17.5) 16.0 (15.2-16.7) 0.034 
Haemoglobin (g/dl) 13.0 (12.7-13.5) 12.4 (11.9-13) 0.043 
PaO2 (mmHg) 77.09 (71.70-82.48) 72.29 (69.11-75.46) 0.13 
pHa 7.412 (7.408-7.417) 7.408 (7.396-7.420) 0.86 
PaCO2 (mmHg) 38.27 (37.27-39.26) 37.88 (36.46-39.31) 0.66 
RE 90 (83-96) 92 (86-97) 0.394 
SE 86 (79-92) 91 (84-97) 0.33 
Te (C) 36.5 (36.2-36.7) 36.7 (36.2-37.0) 0.6 
CPB duration (min) 83 (74-92) 89 (69-109) 0.625 
 
Table 3: Intraoperative parameters before anaesthesia induction. The serum glucose level and initial 
cerebral tissue oxygen saturation (CrSO2) with parameters determining tissue oxygen balance. MAP: mean 
arterial pressure; CaO2: arterial oxygen content; PaO2: arterial partial pressure of oxygen; PaCO2: 
arterial partial pressure of CO2; RE: response entropy; SE: state entropy, Te: oesophageal temperature, 
CPB: cardiopulmonary bypass. Data are shown as mean and 95% confidence interval for the mean 
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Effects of T2DM on central venous and cerebral oxygen saturation during CPB and OPCAB 
procedures 
Oxygen saturation in central venous blood (ScvO2), in cerebral tissue (CrSO2) and their difference 
expressed as a saturation gap (gSO2), are presented in Fig 12 for the patients underwent cardiac 
surgery with (top) or without (bottom) CPB. No significant difference was observed in ScvO2 
between patients with and without T2DM at any protocol stage. Conversely, CrSO2 was 
significantly lower in the T2DM-CPB and T2DM-OPCAB groups than in the corresponding 
controls (p<0.001 for both), and this difference endured in all phases of the surgery. This result 
was reflected in significant differences in gSO2 between patients with and without T2DM in the 
CPB and OPCAB patients (p<0.001 for both). During the surgical procedure, prominent and 
significant increases in ScvO2 (p<0.001) with smaller but statistically significant decreases in 
CrSO2 (p<0.05) were observed at the beginning of CPB, resulting in marked elevations in gSO2 
(p<0.001). In both CPB groups, the ScvO2 and gSO2 reversed by the end of CPB, and these 
parameters decreased below their initial levels in C-CPB patients (p<0.005). No significant 
intraoperative changes were observed in the oxygen saturation parameters in the OPCAB patients. 
Effects of T2DM on clinical parameters affecting cerebral oxygen supply and demand 
Main clinical parameters characterizing tissue oxygen balance obtained at different stages of the 
protocol are summarised in Figs 13-16. Between-group differences were observed only in the 
CaO2 before the surgical procedure (Fig 13, p<0.05) in the blood glucose levels throughout the 
surgery (Fig 16, p<0.05) and in the arterial oxygen saturation CrSO2 differences (Fig 13 p<0.05). 
Considerable within-group intraoperative changes were observed primarily during the CPB 
procedure. The onset of CPB was associated with small but significant decreases in core body 
temperature in both T2DM-CPB and C-CPB patients (Fig 15, p<0.05), which subsequently 
returned to the initial value by the end of the surgery. Furthermore, MAP and CaO2 decreased 
significantly in both groups of patients when CPB was established (Fig 13, p<0.05), and returned 
to their initial values following chest closure. RE and SE decreased significantly after anaesthesia 
induction in all groups of patients with no difference between patients with and without T2DM 
(Fig 15).
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Figure 12. The central venous oxygen saturation (ScvO2, panels A and D), the cerebral oxygen 
saturation (CrSO2, panels B and E) and the differences between these indices (gSO2, panels C and F) 
according to the protocol stages in patients with (red symbols) and without T2DM (black symbols) who 
underwent CPB (top panels) or OPCAB procedures (bottom panels). Error bars represent the following: 
SD. : p<0.001 between the protocol groups within a stage, #: p<0.05 vs. stage “After Ind.”, $: p<0.05 
vs. condition “Start CPB”, §: p<0.05 vs. condition “End CPB” within a group
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Figure 13. Intraoperative changes in the parameters determining cerebral-tissue oxygen supply in patients 
with (n=48, red symbols) and without (n=91, black symbols) diabetes mellitus. CPB procedures on the top, 
OPCAB procedures are on the bottom panels. MAP: mean arterial pressure, CaO2: arterial oxygen content, 
pHa: arterial pH. *: p<0.05 control vs. T2DM, +: p<0.05 vs. before induction, #: p<0.05 vs. after induction, 
$: p<0.05 vs. start CPB or OPCAB, §: p<0.05 vs. end CPB. 
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. 
Figure 14. Intraoperative changes in the oxygenation index (PaO2/FiO2), arterial oxygen saturation 
(SaO2) and the differences between arterial and central venous (SaO2-ScvO2) and cerebral-regional 
saturation (SaO2-rSO2) (n=48, red symbols) and without (n=91, black symbols) diabetes mellitus. CPB 
procedures on the top, OPCAB procedures are on the bottom panels. *: p<0.05 control vs. T2DM, +: 
p<0.05 vs. before induction, #: p<0.05 vs. after induction, $: p<0.05 vs. start CPB or OPCAB 
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Figure 15. Intraoperative changes in the parameters determining cerebral-tissue oxygen demand in 
patients with (n=48, red symbols) and without (n=91, black symbols) diabetes mellitus. CPB procedures 
on the top, OPCAB procedures are on the bottom panels. Te: oesophageal temperature, RE: Response 
Entropy, SE: State Entropy. +: p<0.05 vs. before induction, #: p<0.05 vs. after induction, $: p<0.05 vs. 
start CPB or OPCAB, §: p<0.05 vs. end CPB 
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Figure 16. Intraoperative changes in serum 
glucose levels in patients with (n=48, red 
symbols) and without (n=91, black symbols) 
diabetes mellitus. CPB procedures on the 
top, OPCAB procedures are on the bottom 
panels. *: p<0.05 control vs. T2DM, +: 
p<0.05 vs. before induction, #: p<0.05 vs. 
after induction, $: p<0.05 vs. start CPB or 
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Relationship between central venous and cerebral oxygen saturation: effects of T2DM 
The relationship between central venous and cerebral oxygen saturation obtained after anaesthesia 
induction prior to the surgery for control and T2DM patients is illustrated in Fig 17. Significant 
correlation was observed between ScvO2 and CrSO2 in the control group. In contrast, no significant 
correlation was found between these global and regional oxygen saturation parameters in patients 
with T2DM.  
 
Figure 17. Correlation between cerebral oxygen saturation (rSO2) and central venous oxygen 
saturation (ScvO2) after the induction of anaesthesia in each patient. Linear regression in the T2DM 
group (p=0.34, r=0.13), Linear regression in the control group (p<0.0001, r=0.52). 
 
42 
 
DISCUSSION 
In diabetes, detrimental changes on molecular, cell and tissue level lead to multiorgan damage. 
While the effects of diabetes are studied excessively, there are still lack of knowledge how diabetes 
affects distinct organs. Thus, we investigated the impact of diabetes on two vital organs, the lung 
and the brain. Chronic hyperglycaemia lead to pathophysiological intracellular pathway activation 
resulting in i.e. ROS overproduction, PKC-activation, TGF-β overexpression, glycation (Fig 1.). 
The resulted IC and EC protein, endothelial and epithelial damage manifest in vascular and 
bronchial smooth muscle cell and connective tissue dysfunction, leading to deteriorations both in 
the respiratory system and in the brain. The respiratory consequences of DM were studied in well-
established rodent models, which allowed the use of complex measurement techniques without the 
influence of other potentially confounding factors (i.e. age, the onset of the disease, or 
comorbidities). The cerebral effects were investigated in a patient population in which the presence 
of diabetes is more frequent and susceptible to further organ damage. Since diabetes affects 
approximately one third of the patients undergoing cardiac surgery, a surrogate of the tissue 
oxygenation, the CrSO2 was measured before and during cardiac surgery to elucidate the effect of 
diabetes on cerebral tissue oxygenation.  
Effect of diabetes on the respiratory system: experimental study 
The characterization of the pulmonary effects of DM in this study revealed detrimental changes in 
airway function, viscoelastic tissue mechanics, gas exchange, and collagen expression in the lung, 
with more severe manifestations in the rat model of type 1 DM than in that for type 2 DM. The 
increase in the basal airway tone with DM was associated with compromised dissipative and elastic 
tissue mechanics. The model of type 1 DM also showed diminished airway responsiveness to an 
exogenous cholinergic stimulus. These adverse mechanical and functional changes were 
accompanied by an increased intrapulmonary shunt and impaired PaO2/FiO2. Increasing the lung 
volume had a beneficial effect on the lung mechanics in both diabetic groups, whereas it had no 
benefit on gas exchange. 
This study used well-established models to induce type 1 and 2 DM [101-106]. Type 1 DM was 
induced by a single high dose of STZ to cause the destruction of the pancreas, whereas type 2 DM 
was induced by a low dose of STZ to cause diffuse degeneration of the pancreatic cells, combined 
with a high-fat diet. As a result of these treatments, the blood glucose levels in both DM groups 
were markedly higher after 12 weeks than those of the control group. The body weight of the type 
1 DM group rats was reduced, which can be explained by insulin deficiency [117, 118]. As with 
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other chronic complications of DM, the pulmonary complications would be expected to manifest 
in the late stage of the condition [21]. For this reason, a 12-week period was allowed for the animals 
to develop lung dysfunction. This long period with markedly elevated serum glucose levels 
allowed the development of adverse pulmonary symptoms without a fatal outcome. 
Changes in the mechanical properties of the respiratory system 
Forced oscillatory assessment of airway mechanics showed that DM caused a deterioration of 
basal Raw, with more severe changes occurring in the type 1 DM model rats (Fig 8 PEEP0). As 
these changes were also apparent in the specific airway resistance values (Table 1) of both DM 
groups, the differences in lung sise cannot solely be accounted for by the compromised airway 
mechanics. Instead, these pathological changes in the airways may be explained by the decreased 
vagal tone [119], excessive mucus production [120], low-grade chronic inflammation [121], 
activation of inflammatory pathways [122], or bronchial smooth muscle cell proliferation [123, 
124]. The present study’s finding of increased airway tone in the DM rat models is in qualitative 
agreement with the results of previous studies that assessed airway resistance in DM [45, 125], 
providing supporting evidence for the potential development of chronic airway obstruction in 
patients with DM. 
The effects of DM on the mechanical properties of the lung tissue has been studied in an ex-vivo 
experiment, and the results were limited to assess the elastic behaviour of the lung parenchyma 
[52] However, dissipative properties of the lung tissue play an important role in determining the 
physiological lung mechanics and the changes of this component is characteristic in various lung 
diseases [126]. In the present study using an in-vivo setting, significant deteriorations were 
observed in the viscoelastic mechanical parameters of the respiratory tissues in both groups of 
diabetic rats (Fig 8), and this adverse change affected both the dissipative and elastic properties. 
These differences compared to the control group remained after normalization of the values to the 
FRC (Table 1), indicating that intrinsic changes to the dissipative and elastic properties of the 
respiratory tissues can be anticipated. Collagen is the main determinant of overall lung tissue 
viscoelasticity [127, 128]. In the present study, the volume of collagen increased in the DM 
models, in agreement with results reported for patients with DM [129] (Fig 11). There were 
significant correlations between the histological and mechanical findings (Fig 12), which 
suggested that the overexpression of collagen may be a primary cause of the compromised tissue 
damping and elastance observed in DM. The underlying pathophysiological mechanisms 
responsible for this extracellular matrix remodelling may be related to the activation of 
pathological pathways that contribute to the formation of AGEs, which also stimulate the 
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production of extracellular matrix components, including collagens, thereby affecting the 
interactions of the extracellular matrix [13]. 
Effect of PEEP on respiratory function 
Increasing numbers of patients with DM require surgical procedures that involve mechanical 
ventilation, which has increased the burden on healthcare providers [130, 131]. There is, therefore, 
a need for awareness that adequate mechanical ventilation should be provided for these patients. 
Open lung strategies require the application of an appropriate PEEP; however, the impact of different 
levels of PEEP on respiratory function in DM has not been clarified. Our findings demonstrated 
that the between-group differences in the airway resistance and in the tissue mechanical parameters 
representing viscoelastic dissipation and elastance disappeared at a moderately elevated PEEP 
(6 cmH2O; Fig 7). The excessive PEEP dependence of the respiratory mechanical parameters was 
consistent with the diminished surfactant function reported previously in models of DM [36, 37]. 
It suggests that applying PEEP can have a beneficial effect on respiratory mechanics in this 
metabolic disease. The mechanical improvements were reflected in the decreased intrapulmonary 
shunt and increased PaO2/FiO2 in the DM rats when a PEEP of 3 cmH2O (Fig 10) was applied. 
Nevertheless, substantial differences remained even with elevated PEEP in both groups of DM 
rats; this can be attributed to the persistent alveolar-capillary barrier damage observed in DM [44, 
129, 132]. The type-II pneumocyte and surfactant layer damage [36, 37] along with the low-grade 
inflammation [44] observed in DM can contribute to the alveolo-capillary dysfunction. Noticeably, 
there was recurrent deterioration of PaO2/FiO2 and Qs/Qt in the type 1 DM rats at a PEEP of 
6 cmH2O. This group would be expected to develop the well-established adverse pulmonary 
vascular consequences of hyperglycaemia [133]. Accordingly, formation of AGEs as detailed 
above contributes to a proliferation of pulmonary endothelial and vascular smooth muscle cells 
and thicker basal lamina [134], which may have resulted in the intra-acinar and alveolar arterioles 
becoming prone to collapse when the PEEP exerted an external mechanical load on the capillary 
network.  
Changes in airway response to exogenous stimuli 
An important physiological feature of airways is the adaptation of their caliber in response to 
exogenous stimuli. The results for the type 1 DM group demonstrated diminished airway 
responsiveness to MCh, which indicated that the adaptation ability of the bronchomotor tone had 
been severely compromised. Pathophysiological mechanisms that may have been involved in the 
decreased airway responsiveness include compromised vagal tone development due to autonomic 
diabetic neuropathy [119, 135], smooth muscle cell dysfunction [136], and/or epithelial damage 
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[29]. Hyperinsulinemia, insulin resistance and hyperglycemia can lead to hyperproliferation and 
phenotype changing of the airway and bronchial smooth muscle cells and induce tracheal wall 
thickening [123, 124]. The smooth muscle cell damage might occur due to various factors, for 
instance disturbances in the nitric oxide synthesis [29], TGF-β and Rho-associated protein kinase 
pathway activation [32, 137, 138]. Nonetheless, conflicting results have been reported for the 
effects of DM on airway responsiveness. The findings of the present study are consistent with 
earlier findings of a reduction in the bronchial response to cholinergic stimuli in DM [29, 47, 139]. 
Previous reports of no change in airway responsiveness [46, 136, 140] or the development of 
airway hyperresponsiveness [32, 33, 141] may be explained by the insensitivity of the methods to 
assess airway function [136], the lack of airway innervation [32, 33, 140], or the involvement of 
confounding factors, such as, smoking, genetic differences and/or phenotype, and the duration of 
DM [46, 141]. Furthermore, in previous clinical studies, diabetes was often associated with 
comorbidities affecting the respiratory system, which may cause variation in the manifested 
pulmonary effects, and can contribute to the discordant results in the literature.  
Effect of diabetes on the cerebral integrity: clinical study 
Significant reduction of brain tissue oxygen saturation was obtained in the present study in T2DM 
patients. Since this finding was not reflected in the central venous oxygen saturation, the gap 
between ScvO2 and CrSO2 widened significantly and the relationship between these two values 
became uncoupled in patients with diabetes. In the T2DM patient, the oxygen saturation gap 
remained elevated throughout the cardiac surgery procedure. 
Differences in the initial parameters between patients with and without diabetes  
The lower initial CrSO2 (Fig 12, B and E) and the associated widening of gSO2 (Fig 12, C and F) 
in patients with T2DM cannot be attributed to differences in demographic, anthropometric and 
clinical characteristics between the two groups (Tables 2 and 3). In both groups of patients, the 
oxygen demand of the cerebral cortex was expected to be in a uniformly low range throughout the 
surgery, as suggested by the therapeutic entropy levels (Fig 15). While the glucose levels differed 
between normal and diabetic patients (Table 3 and Fig 16), the uniformly negligible extinction 
coefficient in the observed wavelength [142] does not bias our findings. The higher glucose 
concentration of the T2DM group can lead to different light scattering in tissue [143], however the 
magnitude of this methodological artefact is could not be great enough to result in such a 
significant difference in the two study groups. Therefore, this phenomenon could not explain our 
findings on the CrSO2 difference between the diabetic and control groups. The presence of anaemia 
and lower CaO2 in the T2DM patients (Table 3) may contribute to the differences in CrSO2 
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between control and diabetic patients. However, ScvO2 did not differ between the protocol groups 
(Fig 12), suggesting sufficient oxygen supply in all patients under general anaesthesia with muscle 
relaxation when the oxygen demand of the paralyzed skeletal muscle decreases markedly. 
Accordingly, the diminished overall oxygen extraction can be supplied both in patients with 
normal or compromised microcirculation (such as T2DM). Moreover, the widened gap in diabetic 
patients remains after CPB despite the lack of difference in CaO2 and MAP between diabetic and 
non-diabetic patients. Most probably, the compromised CrSO2 can rather be explained by the 
adverse cerebrovascular consequences of T2DM. The pathologic metabolic milieu is characterised 
by hyperglycaemia, insulin resistance and elevated level of free fatty acids [144]. Interruption of 
the vasodilatory insulin signalling pathway diminishes endothelial nitric oxide (NO) synthesis 
[145]. Endothelial NO production is further compromised by the advanced glycation end-products 
[145] and by the increased inactivation of NO by oxidative stress [145]. The reduced NO-mediated 
endothelium-dependent vasodilation increases the vascular tone. The elevated arterial tone and/or 
vascular remodelling facilitated by these mechanisms are associated with low-grade inflammatory, 
prothrombotic proliferative processes, resulting in atherosclerotic plaque formation [146]. All 
these mechanisms converge to an impaired microcirculation [8], which may be reflected in 
impaired cerebral-tissue oxygen saturation.  
The few previous results available for anaesthetised patients measured before surgical intervention 
revealed somewhat lower cerebral oxygen saturation in diabetic than non-diabetic patients [99, 
147, 148], or failed to demonstrate an effect of diabetes on this outcome [149]. The discrepancies 
between these earlier results and the current finding may be attributed to the relatively small 
number of patients involved in the previous studies. Considering the substantial inter-individual 
variability in our CrSO2 data obtained in diabetic patients (Fig 12), the statistical power may not 
have been robust enough to reach a conclusion with confidence in the previous studies. All these 
previous studies applied jugular venous bulb oximetry to assess cerebral oxygen saturation, which 
reflects the oxygen status of the entire brain, whereas NIRS utilised in the present study focuses 
on the cortex. Since both the blood flow and oxygen demand is higher in the cortex than in the 
white matter [98], microvascular dysfunction and remodelling may be more apparent in the cortical 
region. The sole previous study where NIRS data were reported for a diabetic subpopulation was 
part of a preoperative assessment without evaluating changes in the intraoperative period [150]. In 
this study, diabetes was associated with lower baseline CrSO2 in vascular surgery patients; 
however, patients undergoing cardiac surgery procedures exhibited no difference preoperatively. 
Nevertheless, the high ratio of smokers and inclusion of aged patients in this previous study may 
have blunted the distinct effects of diabetes on the measured outcomes. 
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Intraoperative changes  
Remarkable intraoperative changes were observed in ScvO2, CrSO2 and gSO2 at the beginning of 
CPB (Fig 12, top panel). The increases in ScvO2 can be attributed to a decreased core temperature 
(Fig 15) and subsequent decrease in the systemic oxygen demand [151]. The concomitant slight, 
but significant, decrease in CrSO2 in the diabetic patients should be interpreted in terms of a 
decreased MAP and haemoglobin concentration associated with an elevation in arterial pH 
(Fig 14) [152]. The opposite changes in ScvO2 and CrSO2 after the onset of CPB are reflected in 
the striking elevations in gSO2 (Fig 11 C). It is of note that in diabetic patients the gSO2 may rise 
to a value threefold greater than physiologically normal (i.e. from around 10 to around 30 %, 
Fig 12 C). The compromised CrSO2 observed in the present study may be responsible for the 
increases in postoperative adverse neurocognitive outcomes and stroke in T2DM patients [92-95]. 
In contrast with the CPB patients, no intraoperative changes in oxygen saturation indices were 
detected in the patients with OPCAB procedures (Fig 12, bottom panel). This more stable pattern 
of cerebral-tissue oxygen saturation may explain the lower incidence of postoperative stroke [94, 
153] and cognitive dysfunction [154] after cardiac surgery with OPCAB. 
The brain has high oxygen demand as well as low hypoxic tolerance and the regulation of 
cerebrovascular circulation is correspondingly complex [155]. Therefore, the oxygen saturation of 
this organ can distinctly differ from the rest of the systemic circulation. NIRS offers a simple, non-
invasive, real-time monitoring tool to quantify the oxygen status of brain tissue. Hence, this 
technique has a great potential to reveal disturbances in the regional oxygen saturation promptly, 
with a particular advantage of assessing cerebral tissue oxygen saturation in the perioperative 
period. In non-diabetic patients, there is a significant difference between global and cerebral-tissue 
oxygen saturations, although they exhibit significant correlations (Fig 17). Nevertheless, there is 
a scatter in this relationship due to recognised interindividual variability in even in the control 
patients [156, 157]. Nevertheless, the associations between these regional and global oxygenation 
indices suggest the possibility to predict of the brain oxygen status from the ScvO2 value when the 
cerebral circulation is intact. Conversely, our results also demonstrate that in addition to the gap 
between ScvO2 and CrSO2, these parameters became uncoupled in diabetic patients (Fig 17). The 
lack of a clear relationship between these indices impedes the assessment of cerebral-oxygen 
saturation from ScvO2 in the T2DM population. Accordingly, our findings demonstrate the 
particular monitoring value of NIRS in the presence of a disease affecting cerebral 
microcirculation. These considerations may contribute to the clarification of the monitoring value 
of NIRS in a critically ill population, which is currently under debate [158-161].  
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LIMITATIONS OF THE STUDIES 
Several methodological aspects of the present studies warrant consideration. As well-established 
models were adapted in the experimental study to produce the most important features of DM, 
including hyperglycaemia and insulin deficiency, verification of the effectiveness of the STZ 
treatments was limited to evaluating serum glucose levels; a detailed characterization of the 
resulting metabolic profile would go beyond the focus of the present investigation. The models of 
type 1 and type 2 DM differed only in the dose of STZ and the diet regimen. The high dose of STZ 
administered to the rats in the type 1 DM group was likely to destroy most of the pancreatic β-
cells, whereas less severe β-cell destruction in the type 2 DM group was complemented by a high-
fat diet to induce a combination of impaired insulin production and peripheral insulin resistance 
[102, 118]. The difference in body weight between the groups suggested marked differences in 
their metabolic status; however, the respiratory consequences were analogous in the two DM 
groups, with symptoms differing only in severity. The animal study was designed to focus 
primarily on the changes in the mechanical properties of the respiratory system in diabetes. 
However, there are plethora of diagnostic tools to characterise pulmonary dysfunction both at on 
organ and at cellular levels. Analyses of bronchoalveolar lavage fluid to assess altered surfactant 
function, or quantitative collagen and smooth muscle cell assays by using immunohistochemistry 
methods would give further insights into the underlying mechanisms; these methods may be 
subjects of forthcoming investigations. 
A methodological aspect of the clinical study is related to the general limitations of the NIRS in 
the accurate assessment of cerebral oxygenation, such as lack of established baseline values, 
possible contamination by scalp tissue, localised reading and the assumption of fixed arterial-
venous blood ratio of the tissue [158, 162]. The INVOS-monitor is considered in the first place as 
a trend monitor. However, several studies reporting the absolute values of the CrSO2 [163, 164], 
despite the high interindividual variability. In our study, this variability existed, but the high 
number of involved patients enabled to observe a statistically significant difference in the two 
groups. Another methodological aspect concerns the interindividual variability in the cardiac 
surgery patients. However, the groups of the patients with and without T2DM did not differ in 
anthropometric parameters, diagnoses or surgical procedures, and the comorbidities with potential 
biasing effect on cerebral circulation were excluded. This study focused on the intraoperative 
changes of tissue oxygenation, further studies are required to follow-up potential differences in the 
clinical outcomes (e.g. stroke or neurocognitive dysfunction) between normal and T2DM patients. 
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SUMMARY AND CONCLUSION 
The studies included the present thesis emphasise the diabetic consequences both on the 
respiratory and cerebral function and contribute to better understanding the effect of diabetes on 
these organs. We demonstrated that diabetes deteriorates respiratory function, but PEEP elevation 
is beneficial for the mechanical properties, whereas it was not advantageous on the gas exchange 
parameters and oxygenation. As a consequence of the diabetic pathophysiological milieu, the 
cerebral regional oxygen saturation was compromised and the gap between CrSO2 and ScvO2 
widened suggesting that the cerebral autoregulation is impaired. These deteriorations originate 
from the complex yet common pathophysiological changes in diabetes. 
As a summary of the experimental study, distinct measurements of airway and respiratory tissue 
viscoelastic parameters in models of T1DM and T2DM showed evidence of detrimental changes 
in both compartments. The decline in airway function was reflected in elevated airway resistance 
and abnormal adaptation of the airways to exogenous constrictor stimuli. Lung tissue remodelling 
was manifested in compromised viscoelastic tissue mechanics, which affected dissipative and 
elastic properties, and the concurrent overexpression of collagen fibres in the extracellular matrix. 
These detrimental mechanical defects were overcome by applying PEEP, which demonstrated 
alveolar collapsibility in DM. However, even with the application of PEEP, gas exchange 
parameters remained compromised in the models of type 1 and type 2 DM, even deteriorated 
further in the type 1 DM model, indicating alveolo-capillary dysfunction. 
Damages in the cerebral function are well known, however there were no study previously 
comparing the rSO2 between diabetic and control in anaesthetised patients during cardiac surgery. 
Furthermore, the relationship between the cerebral regional and the central venous saturation was 
not clarified earlier. The clinical study included in the present thesis demonstrated that diabetes 
mellitus worsens the oxygen saturation of the cerebral tissue and uncouples indices reflecting 
regional cortical and global central venous oxygenation. Consequently, disturbances in the cortical 
oxygen saturation in diabetic patients become unpredictable from the well-established global 
clinical parameter of central venous oxygen saturation. Thus, diabetic patients may benefit from 
the continuous intraoperative measurement of CrSO2 to optimise tissue oxygenation with adjusting 
cerebral perfusion pressure, arterial oxygen content and/or avoiding alkalosis. 
In conclusion, the studies included in the present thesis are contributing to better understanding 
the detrimental effects of diabetes mellitus. Thus, the results foster better clinical practice 
contributing advanced therapeutic intervention, and safer perioperative patient care. 
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